Previous studies have demonstrated that antigen-specific tolerance could be induced by lipopolysaccharide (LPS)-stimulated B cells retrovirally transduced with an immunoglobulin-antigen (or epitope-containing peptide) fusion construct. To investigate the mechanism of this gene therapy system, we now adapted this approach to immunotherapy of spontaneous diabetes in nonobese diabetic (NOD) mice, a T-cell-mediated autoimmune disease triggered, in part, by a pathogenic response to glutamate decarboxylase (GAD) 65. We demonstrate that LPS-stimulated splenocytes, retrovirally transfected with GAD-IgG fusion construct, induce a significant antigen-specific hyporesponsiveness at both cellular and humoral levels and reduce the incidence of diabetes in female NOD mice. Parallel with disease protection, we observed a prolonged increase of the numbers of CD4 + regulatory T cells in GAD-IgG-treated mice during the prediabetic period and serum TGF-b levels in 34-38-week-old GAD-IgG-protected mice were also increased, compared to control IgG-treated ones. Therefore, we propose that the induction of tolerance and the prevention of diabetes incidence in NOD female mice induced by the GAD-IgG fusion construct may require CD4 + regulatory T cells, and the possible mediation of TGF-b.
Previous studies have demonstrated that antigen-specific tolerance could be induced by lipopolysaccharide (LPS)-stimulated B cells retrovirally transduced with an immunoglobulin-antigen (or epitope-containing peptide) fusion construct. To investigate the mechanism of this gene therapy system, we now adapted this approach to immunotherapy of spontaneous diabetes in nonobese diabetic (NOD) mice, a T-cell-mediated autoimmune disease triggered, in part, by a pathogenic response to glutamate decarboxylase (GAD) 65. We demonstrate that LPS-stimulated splenocytes, retrovirally transfected with GAD-IgG fusion construct, induce a significant antigen-specific hyporesponsiveness at both cellular and humoral levels and reduce the incidence of diabetes in female NOD mice. Parallel with disease protection, we observed a prolonged increase of the numbers of CD4 + CD25
+ T cells in the periphery of GAD-IgG-treated mice, compared to those treated with a control IgG vector, both in the prediabetic period and persisting even 8 months after gene therapy. This increase appeared to be induced by the repeated stimulation of the antigen in the periphery instead of a result of differentiation of T-cell precursor in the + regulatory T cells in GAD-IgG-treated mice during the prediabetic period and serum TGF-b levels in 34-38-week-old GAD-IgG-protected mice were also increased, compared to control IgG-treated ones. Therefore, we propose that the induction of tolerance and the prevention of diabetes incidence in NOD female mice induced by the GAD-IgG fusion construct may require CD4
Introduction
Induction of specific tolerance to the autoantigens without affecting the remainder of the immune system is an ideal approach to the treatment of autoimmune diseases. A number of experimental procedures have been proposed to induce tolerance to autoantigens and therefore to prevent and/or reverse autoimmunity as an ultimate goal. [1] [2] [3] Based on the tolerogenic properties of immunoglobulin (Ig) carriers and the efficacy of B-cell antigen presentation for unresponsiveness, our colleagues designed a novel gene therapy approach using Ig-antigen fusion protein(s) delivered via retroviral vectors in B cells for the induction of specific tolerance. 3 Briefly, a flexible fusion protein construct, consisting of an epitope-containing peptide (or the full-length antigen) in frame at the N-terminus of an IgG heavy chain was created. When this Ig-fusion protein was delivered into bone marrow (BM)-derived cells or lipopolysaccharide (LPS)-stimulated B cells via retroviral infection, and then these cells were injected into syngeneic recipients, the recipients were rendered significantly hyporesponsiveness to specific epitopes of the antigen. [3] [4] [5] [6] [7] [8] [9] [10] Results with this gene therapy protocol demonstrated that it was simple and effective, even in primed recipients and autoimmune animals, including preliminary studies with spontaneous diabetes in nonobese diabetic (NOD) mice. 6, 10 However, the precise mechanism of tolerance induction in this system is not well understood. We know that tolerance does not involve a Th1/Th2 shift, 4, 10 that major histocompatibility complex (MHC) class II expression on the presenting B cells is important and B cells are critical antigen-presenting cells (APCs), 7 but that Fc receptors are not required. 8 To further examine the mechanism of tolerance induction by retroviral delivery of Ig tolerogens in B cells, we utilized this gene transfer approach in the treatment of spontaneous diabetes in NOD mice, an animal model for human insulin-dependent diabetes mellitus (IDDM). This model is characterized by the T-cell-mediated destruction of the insulin-producing pancreatic b-cells. 11 The 65 kDa form of glutamic acid decarboxylase (GAD65) has been shown to be a key islet cell autoantigen in the induction of diabetes in NOD mice. 10 The initial autoimmunity to GAD65 triggers a spreading T-cell response to other pancreatic b-cell antigens; importantly, tolerance induction to GAD65 can block the spreading to other b-cell antigens, thus preventing diabetes. 12, 13 In this study, a retroviral construct encoding full-length pathogenic murine GAD65 at the N-terminus of murine IgG scaffold was used to treat NOD mice by delivering retrovirally genetransfected LPS-stimulated splenocytes. Herein, we demonstrate that GAD-IgG fusion construct could induce significant antigen-specific hyporesponsiveness at both cellular and humoral levels, and protect against the onset of diabetes in NOD mice. We also have focused on characterizing the contribution of the immunoregulatory T cells and cytokines to the prevention of diabetes in this gene therapy system. Our results suggest that the numbers of CD4 + CD25
+ and CD4 + CD62L + regulatory T cells were increased during tolerance induction and/or maintenance in treated NOD mice, which also express an increasing level of serum transforming growth factor (TGF)-b. The roles of these factors in the gene therapy for tolerance in GAD-IgG-protected mice deserve further study.
Results

Recipients of LPS-stimulated splenocytes transduced with GAD-IgG construct are protected from diabetes in NOD mice
Previous studies demonstrated that antigen-specific tolerance could be induced by LPS-stimulated B cells or splenocytes retrovirally transduced with a peptide or protein-IgG fusion construct. [3] [4] [5] [6] [7] [8] [9] [10] In this study, we utilized and extended this methodology in order to evaluate the mechanism of tolerance in the immunotherapy of spontaneous diabetes in NOD mice. GAD65 is a well-studied pathogenic autoantigen in the triggering of autoimmune IDDM in NOD mice. 12, 13 Therefore, a moloney leukemia retroviral vector (MBAE) containing full-length GAD in frame on the IgG scaffold (GAD-IgG/ MBAE) was used in this study, as was previously employed in the treatment of prediabetic female NOD mice. 10 As shown in Figure 1A , a single infusion of splenocytes retrovirally transduced with GAD-IgG/ MBAE construct afforded significant protection from diabetes when given to 7-week-old NOD mice, compared to recipients of the mock control or IgG-treated B cells. While 55% of GAD-IgG-treated NOD mice eventually developed diabetes (which was delayed in onset), all of the mice from IgG-treated and mock control groups developed diabetes starting on 28 weeks of age. Moreover, the suppression of diabetes in GAD-IgG-treated group persisted for over 8 months, indicating a longterm protective effect on autoimmunity by this gene therapy protocol.
Diabetes is usually associated with inflammatory cells that accumulate in the pancreas islets. The histopathology in the pancreas of 38-week-old GAD-IgG-protected NOD mice or the diabetic ones from IgG-treated group was shown in Figure 1B . Destruction of the islets was significant in the diabetic NOD mice from Ig group. By contrast, in GAD-IgG-protected mice, intact islets and minimal inflammatory cells infiltration of the pancreas were observed, corresponding to the prevention of diabetes in this group.
Decrease in antigen-specific humoral and cellular response in GAD-IgG-treated mice A pathogenic autoimmune response to GAD65 is believed to be one triggering event for the induction Figure 1 Effect of gene therapy with GAD-IgG retrovirally transduced splenocytes on diabetes incidence of recipient female NOD mice. (A) Groups of nine female recipient NOD mice (6.5-7-week-old) were treated with LPS-stimulated splenocytes from donor NOD mice (5-10-week-old) transduced with the mock control, IgG or GAD-IgG fusion construct. Mice were screened for glucose levels every 1-2 weeks after gene therapy and considered diabetic when glucose levels X250 mg/dl were detected at two consecutive measurements. Statistical analysis of the glucose levels between GAD-IgG and IgG-treated groups, by weeks, reach significant difference (Po0.01) 21 weeks after gene therapy (the mice are 28-week-old at this time point). Results of diabetes incidence (number of diabetic out of total mice) represent a typical experiment. (B) Histopathology of pancreatic islets from: (a) untreated diabetic female NOD mice; (b) untreated nondiabetic mice or (c) diabetic mice from IgG-treated group or (d) GADIgG-protected NOD mice. Mice of the four groups were all 38 weeks old. The pancreas were isolated from the individual mice described above and the islet-infiltrating cells were detected by hematoxylin and eosin staining. Destruction of islets can be observed in diabetic NOD mice from the untreated (a) or IgG-treated group (c) of the same age. By contrast, intact islets were obvious in GAD-IgG-protected mice (d), which were similar to naïve nondiabetic ones (b).
Influence of GAD-IgG fusion construct on diabetes L Song et al of diabetes in NOD mice. 12, 13 In addition, a cascade of response to different epitopes of GAD65 exists. The initial Th1 response appears to be directed against two adjacent regions of the antigen (p509-523 and p524-543); later, the response spreads to an additional region (p246-266) and other autoantigens expressed by islet cells. 11, 12 Based on the T-cell epitope prediction results, the dominant epitopes of GAD65 are located in the Cterminal region (residues 500-585), while subdominant epitopes appear to be compactly located in the middle region (residues 200-300) of this protein (J Feng et al, unpublished data). To evaluate epitope-specific humoral and cellular response in treated mice, two fragments of GAD65 corresponding to GAD 500À585 (GADg2) and GAD 200À300 (GADg1), which would be expected to contain the dominant and the subdominant T-cell epitopes of this protein, were prepared and purified from Escherichia coli. The antigenicity of the two polypeptide fragments was verified by enzyme-linked immunosorbent assay (ELISA) and Western blot analysis (data not shown).
For the measurement of antigen-specific humoral response, anti-GADg1 and GADg2 antibody titers were tested in the serum of the recipient mice infused with the transduced cells 10 days after gene therapy, a time at which control female mice normally show an anti-GAD response. As shown in Figure 2a and b, both the antibody responses to GADg1 and GADg2 were reduced significantly in GAD-IgG-treated mice compared to the control mice from IgG-treated group (*Po0.05 and **Po0.01). Moreover, the specific antibody response to GADg1 was about 5-10-fold lower than that to GADg2 in all animals at the time point investigated (note the scales in the figures). This confirms that the responsive strengths to the two epitopes of GAD65 are different in prediabetic period in NOD mice. Antibody titers to an unrelated histagged polypeptide (UP) were also tested in this assay as a specific control. No antibody response (the titers were p10) to the UP control antigen was detected in all serum samples ( Figure 2c ).
The GAD-specific T-cell response was evaluated by in vitro proliferation of the splenocytes and the lymph node cells stimulated by GADg1 and GADg2. As shown in Figure 3a , injection of GAD-IgG-gene-transferred B cells resulted in significant hyporesponsiveness of splenocytes to both GADg1 and GADg2, compared to the IgG-treated group (*Po0.05 and **Po0.01). However, no statistical differences on the proliferative responses to ConA or UP between the two groups were observed, respectively (P40.05). GAD-specific proliferation of the lymph node cells was essentially identical to the splenocyte response (Figure 3b ).
In addition, both Th1-and Th2-type cytokines production in response to the recall antigen were Figure 2 Humoral hyporesponsiveness to GADg1 and GADg2 in NOD mice receiving GAD-IgG-transduced splenocytes. Anti-GADg1 and GADg2 antibody titers in NOD mice were determined by ELISA 10 days after i.v. injection of GAD-IgG-or IgG-transduced splenocytes. Antibody titers were calculated as the dilution of test serum needed to reduce the signal level to three-fold of the signal from the serum of BABL/C mice with same dilutions. Both the antibody responses to GADg1 and GADg2 were reduced significantly (*Po0.05 and **Po0.01) in GAD-IgG-treated mice (triangle) comparing with the control mice from IgG-treated group (circle). No antibody response to the specific control, an unrelated his-tag polypeptide (UP) was observed in this assay. One set of five repeated experiments is shown, with four mice per group. Influence of GAD-IgG fusion construct on diabetes L Song et al determined from in vitro culture supernatants. As shown in Figure 4a , GADg2 significantly stimulated the splenic interleukin (IL)-2 production in both IgG-and GAD-IgGtreated mice (**Po0.01); however, IL-2 induction in the splenocytes of GAD-IgG-treated mice was lower than that of IgG-treated group (3.670.38-fold versus 5.870.67-fold of the individual unstimulated control, respectively. **Po0.01). Splenic productions of interferon (IFN)-g and IL-4 in response to GADg2 were only observed in recipient mice of IgG-gene-transduced cells (*Po0.05 and **Po0.01) instead of in GAD-IgG-treated group (Figure 4b and c) . These data suggest that gene therapy with GAD-IgG fusion construct induces hyporesponsiveness in both Th1 and Th2 cell compartments.
Collectively, the results above indicate that B cells expressing GAD-IgG fusion construct are able to induce GAD-specific hyporesponsiveness at both the cellular and humoral levels in NOD mice. 15 Previous studies have demonstrated that CD4 + CD25 + Treg cells may play a major role in regulating the autoreactive diabetogenic T cells and thus onset of diabetes in NOD mice. 16 Therefore, we tested the hypothesis that GAD-IgG-gene-transferred B cells induced specific tolerance in NOD mice by altering the proportion of these cells. Spleen cells were isolated and the percentage of CD4 + CD25
+ T cells was analyzed by flow cytometry 10 and 20 days after gene therapy. As shown in Table 1 , at the two time points examined, 0.7070.12 and 2.0070.04% of the spleen cells were CD4-and CD25-positive in the control mice, whereas the percentage increased to 2.4970.56 and 4.3370.33% in the spleen cells of GAD-IgG-treated mice, respectively. A similar increase in the percentage of this T-cell subset was also observed in the inguinal lymph nodes (data not shown). These data suggest the involvement of CD4 + CD25 + T cells for the induction of tolerance by the tolerogenic Ig fusion construct in NOD mice.
To further test whether CD4 + CD25 + T cells are also involved in the persistence of tolerance in NOD mice, we next examined the percentage of this T-cell subset in the spleens of 34-38-week-old NOD mice of the two groups. A significant increase in the number of splenic CD4 + CD25 + T cells in GAD-IgG-protected mice (6.5771.19%, Table 1 ) was maintained compared to that in the control diabetic ones (3.2271.15%), indicating also a requirement of this T-cell population for the main- To address this problem, the coculture experiment was performed to determine if CD4 + CD25
+ T cells generated in the periphery of GAD-IgG-treated mice have suppressive effects. CD4 + CD25 + T cells were purified from the splenocytes of GAD-IgG-treated mice using MACS and cocultured them with CD4 + CD25 À T cells in the presence of soluble anti-CD3 mAb plus irradiated splenic APCs. As shown in Figure 5a To further investigate whether the increase in CD4 + CD25 + T cells is related to diabetes prevention in GAD-IgG-treated group, a blocking antibody against CD25 was used to abrogate the activity of CD4 + CD25 + T cells in the in vitro GAD-specific T-cell proliferative response assay. As shown in Figure 5b , addition of CD25 neutralizing mAb instead of its isotype control IgG significantly reversed GADg1-specific T-cell hyporesponsiveness in GAD-IgG-treated mice (**Po0.01). This result implies that CD4 + CD25
+ T cells generating early in GADIgG-treated mice might exert suppressive effect on GADspecific T-cell response in the prediabetic period and thus prevent the following development of diabetes.
Whether the accumulation of CD4 + CD25 + Treg in the periphery is a result of the development and differentiation of precursor T cells in the thymus or a result of peripheral repeated stimulation by the antigen is still controversial. 17 To address this question in our model system, the percentage of CD4 + CD25
+ T cells in the thymus was detected 10 and 20 days after gene transfer. We observed no statistical difference in the proportion of this T-cell subset in the thymus between GAD-IgG and IgG-treated mice at the individual time points ( 
regulatory T cells in tolerance induction
CD4
+ CD62L + T cells are a newly described CD4 + regulatory T-cell subset in the thymus and periphery that can mediate active tolerance during the prediabetic period and prevent the onset of diabetes in NOD mice. 18, 19 We next determined whether there was an increase in this T-cell subset in our model system. (Table 1) . These data are consistent with the involvement of CD4 + CD62L + regulatory T cells in the prevention of diabetes in NOD mice treated with this gene therapy protocol.
Roles of IL-10 and TGF-b in tolerance induction and maintenance IL-10 and TGF-b are immunoregulatory cytokines that are involved in induction and maintenance of peripheral tolerance by affecting autoreactive T-cell-mediated response. [20] [21] [22] The regulatory effects of these two cytokines in the onset of diabetes in NOD mice have been demonstrated previously. 20 In addition, Tr1 and Th3, other two major kinds of CD4 + Treg cells, appear to exert their immunosuppressive roles via the production of high level of IL-10 and/or TGF-b. 21, 22 Therefore, we determined the roles of IL-10 and TGF-b in tolerant NOD mice treated as above. As shown in Figure 6a , 20 days after B-cell gene therapy, we found that secretion of IL-10 was stimulated by GADg1, GADg2 and soluble anti-CD3 antibodies. However, there was no statistical difference on the induction of splenic IL-10 production in the presence of various stimuli between the two groups (P40.05). A similar result was also obtained when the spleen cells from 34-38-week-old GAD-IgG-protected and control diabetic mice were examined (data not shown). This result is consistent with the observations of El-Amine et al 7 and Agarwal et al 6 in other antigenic systems. These data suggest that IL-10 is involved in neither the induction nor the maintenance of tolerance in NOD mice induced by GAD-IgG fusion protein. 
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When levels of TGF-b were examined, we also observed no differences between two groups in the splenic secretion of this cytokine in response to GADg1 and GADg2 in the prediabetic period (Figure 6b ). In addition, a trend of increasing but no difference of serum levels of TGF-b was detected in GAD-IgG-treated mice comparing with IgG-treated group early after gene therapy (Figure 6c) . Notably, serum TGF-b levels of 34-38-week-old GAD-IgG-protected mice were 2-3-fold higher than that of the mock control and IgG-treated diabetic mice (Figure 6d ). These results suggest that TGFb is not required for induction, but appear to be involved in persistence of tolerance in NOD mice treated with GAD-IgG-gene-transduced cells.
Discussion
The effectiveness of the gene therapy protocol using Igantigen fusion protein(s) delivered via retroviral vectors for the induction of specific tolerance opens the possibility of applying of this platform technology in prevention or amelioration of autoimmune disease in a clinical setting. [1] [2] [3] [4] [5] [6] [7] [8] To further understand the mechanism of tolerance induction and maintenance in this system, we first confirmed the efficacy of this gene therapy protocol for tolerance induction in a spontaneous autoimmune disease model, diabetes in NOD mice. Then we focused on the influence of immunoregulatory T cells and cytokines on this gene therapy system.
Gene therapy with GAD-IgG-retrovirally infected B cells led to a significantly decreased incidence of diabetes in female NOD mice compared to recipients of mock control and IgG-expressing B cells. In addition, both the humoral and cellular responses to the GAD protein were inhibited in the GAD-IgG-treated group (Figures 2-4) , suggesting that an antigen-specific tolerance was induced by GAD-IgG fusion protein in NOD mice. In the previous studies, Melo et al 10 presented data that B-cell blasts transduced to express GAD-IgG also showed a delay in the onset of diabetes when treatment was administrated into NOD mice at 7-10 weeks of age. Although the diabetes incidence in NOD mice treated with GAD-IgG fusion protein in their studies (30-40%) was slightly lower than that of ours (55%) when the mice were 24-week-old; their data, however, did not give the information of how long the hyporesponsive state persisted after this time point. 10 In our colony, IDDM appeared by 12 weeks of age and diabetes incidence increased to 80-90% in 30-week-old untreated mice (as similar as the mock control-treated group shown in Figure 1a ). Therefore, we extended our gene therapy experiment in NOD mice to over 8 months period of time, and the results presented in Figure 1a showed that protection of GAD-IgG on diabetes could prolong to 31 weeks after gene therapy, at which time point 100% of the mock control and IgG-treated mice developed diabetes. The prolonged survival to 38 weeks of age of NOD mice received GAD-IgG-transduced cells highlighted the long period of tolerance maintenance in this gene therapy system. The efficacy of B-cell delivered GAD-IgG fusion protein on the prevention of diabetes in NOD mice provides a good model system to further investigate the mechanism of tolerance induced by this retroviral gene delivery method.
Compelling evidence now exists that CD4 + T cells that specialize in the suppression of immune response play a critical role in immune regulation. 14 + Treg can exert a suppressive activity on the destruction of islet b cells by inhibiting the function of autoreactive diabetogenic T cells during the prediabetic period and thus ultimately prevent diabetes onset. 16, 17 Therefore, we hypothesized that the prevention of diabetes in NOD mice by GAD-IgG-transduced cells might, at least partially, due to the regulation on CD4 + CD25 + Treg. Our data indicated that the percentage of CD4 + CD25 + T cells in the spleen (Table 1) and lymph nodes (data not shown) of GAD-IgG-treated mice was significantly higher than that of the IgG-treated group during the prediabetic period. Moreover, this T-cell subset was able to suppress the proliferative response of CD4 + CD25 À T cells in vitro; and CD25 neutralizing monoclonal antibody (mAb) could reverse GAD-specific T-cell hyporesponsiveness in GAD-IgG-treated mice ( Figure 5 ). These data suggest that the prevention of diabetes onset by this gene therapy method result from, as one possibility, the suppression of CD4 + CD25
+ Treg on diabetogenic T cells.
The second possible mechanism for the effects of CD4 + CD25 + Treg on diabetes onset is an inhibition of the migration of effector T cells into the islets, and thus a decreased insulitis severity. Lepault et al 19 24 CTLA-4 is constitutively expressed on the surface of CD4 + CD25 + Treg, 17 and the finding that CTLA-4 is required for the tolerance induction by Ig-fusion protein 7 suggests that this molecule might be involved in the activity of CD4 + CD25
+ Treg by directly giving a negative signal via CD80/86 expression on the tolerogenic APCs.
Apart from CD4 + CD25 + Treg cells, a number of other regulatory T cells and cytokines that have been described to participate in tolerance induction and maintenance. CD4 + CD62L + T cells represent a new immunoregulatory T-cell population that is highly effective at preventing diabetes in NOD mice. 18, 19 The number of CD4 + CD62L
+ + T cells in our system are also coexpressing CD25.
In addition, Tr1 and Th3 are two kinds of Treg cells that are able to suppress naïve and memory Th1 and Th2 response in vivo by producing high levels of IL-10 and TGF-b. 21, 22 The regulation by these two cytokines on the autoreactive T cells and immune pathology in NOD mice have been suggested previously.
11 IL-10 and TGF-b exert their immunosuppressive activity by complex mechanisms, including inhibiting APCs, interfering with the development, proliferation, cytokine production and cytotoxicity of T cells and inducing antigen-specific T-cell anergy, for example. 20 Previous studies by our collaborators failed to show a role of IL-10 in B-cell gene therapy for tolerance using IL-10 knockout mice both as B-cell donors or recipients. 7 In confirmation, we found no difference in IL-10 production either early or late after treatment in NOD mice in our experimental system (Figure 6a ). In contrast, TGF-b was found to be elevated in the serum of long-term tolerant NOD mice (Figure 6d ). Moreover, we have observed a significant difference in the serum level of TGF-b between diabetic and nondiabetic NOD mice of the same age (data not shown), suggesting that maintenance of stable serum TGF-b levels may help to suppress diabetes, whereas decreasing the level of TGF-b promoted the disease. This is consistent with the observation that mice lacking TGF-b may suffer from the progressive infiltration of lymphocytes and inflammation in multiple organs, ultimately leading to death. 22 On the other hand, TGF-b is reported to be required for the expansion or preferential survival of CD4 + CD25 + T cells. 25 Therefore, another possible mechanism for the higher serum level of TGF-b in GAD-IgG-protected mice might simply be a requirement to aid the development and activity of CD4 + CD25 + Treg cells.
In conclusion, our current studies show that the prevention of diabetes in NOD mice following delivery of GAD-IgG-expressing B cells can be used as a model to identify the mechanism of tolerance induction and maintenance by our gene therapy approach. Further work will be necessary to clarify the roles of the upregulation of CD4 + CD25 + and CD4 + CD62L + regulatory T cells, as well as TGF-b in the induction and the maintenance of tolerance.
Materials and methods
Mice NOD mice were obtained from the Jackson Laboratory and bred in our animal facilities under specific pathogenfree conditions. In females, spontaneous diabetes begins to appear by 12 weeks of age (increasing to 80-90% incidence at 30 weeks of age). Mice were screened for glucose levels every 1-2 weeks and considered diabetic when glucose levels X250 mg/dl were detected on two consecutive measurements. The onset of diabetes was dated from the first of the sequential measurements. Donor and recipient female NOD mice in this study aged 5-10 and 6.5-7 weeks old, respectively.
Retroviral constructs and virus-producer cell lines
The MBAE retroviral construct containing full-length GAD fused in frame to the N terminus of murine IgG1 heavy chain (GAD-IgG/MBAE) and the control construct (IgG/MBAE) 8 and the viral producer cell line (GPE86) were prepared and provided by the Scott's lab at the American Red Cross. Virus-producer cell lines were prepared by transfection of GPE-86 packaging cell lines with GAD-IgG/MBAE and IgG/MBAE constructs, respectively. By selected under neomycin (G418, 0.5 mg/ ml), high-titer clones (10 5 -10 6 neomycin-resistant NIH3T3 CFU/ml) were obtained and stored in liquid nitrogen and freshly thawed for each experiment. GPE86 parental cells were used as a mock control. Production of retroviral construct can be confirmed by infection of J558L myeloma cell line by culture of the J558L cells in the presence of the supernatants of the virus-producer cell line.
Retroviral-mediated gene transfer into LPS-stimulated splenocytes for the prevention of diabetes in NOD mice
Retroviral-mediated gene transfer into LPS (Sigma, St Louis, MO, USA)-stimulated splenocytes has been described previously.
1 Briefly, cells (3 Â 10 6 cells/ml) were firstly stimulated with LPS (50 mg/ml) for 24 h, and then cultured in the presence of the supernatants of GAD-IgG or IgG virus-producer cell lines together with Polybrene (6 mg/ml) and LPS (50 mg/ml) for another 24 h. The transduced cells were then injected i.v. (3 Â 10 6 -1 Â 10 7 cells/mouse) into recipient female NOD mice at 6.5-7 weeks of age.
Antigen preparation
The cDNA encoding 200-300 and 500-585 amino acids of murine GAD65 was amplified by PCR and then subcloned into pET28b (+) vector to engineer six histidine residues at the N terminus of the target protein.
Recombinant GAD 200À300 (GADg1) and GAD 500À585 (GADg2) were purified from E. coli BL21 transformed with the recombinant plasmids using Co 2+ /TALON IMAC resin (Clontech) according to the manufacturer's instructions. Eluted GADg1 and GADg2 fractions were dialyzed against PBS (Ph7.2), filter-sterilized and antigenically verified by ELISA and Western blot analysis (data not shown). An unrelated his-tag antigen (UP), which is also prepared and purified from E. coli BL21 in an identical manner to the recombinant GADg1 and GADg2, was used as a specific control in the antibody titers and T-cell proliferation assays. No antibody and T-cell proliferative response to UP were detected in all tested samples.
Measurement of antigen-specific humoral and cellular response in NOD mice
The humoral response was measured in recipient NOD mice 10 days after gene transfer. The serum anti-GADg1 and GADg2 antibodies titers were determined by ELISA analysis by coating plates with 5 mg/ml of the purified his-tagged GADg1, GADg2 or UP. Antibody titers were calculated as the dilution of test serum needed to reduce the signal level to three-fold of the signal from the serum of BABL/C mice with same dilutions. To test the effect of CD25-blocking mAb (rat antimouse CD25, PC61, BD Pharmingen) on GAD-specific T-cell response, the splenocytes of IgG-or GAD-IgGtreated mice were collected 20 days after gene therapy and recalled with GADg1 (30 mg/ml) in the absence or presence of increasing concentrations of PC61, or the same amount of its isotype control IgG, rat IgG1 (BD Pharmingen), for 3 days. [ 3 H]thymidine incorporation was performed as described above. Data are represented when the highest mAb concentration (5 mg/ml) was used.
Determination of cytokines production
The splenocytes were collected 20 days after gene therapy and cultured as for lymphocyte proliferation assay in the presence of GADg1 (30 mg/ml), GADg2 (30 mg/ml), anti-CD3 antibody (clone 2C11, prepared in our lab, 2 mg/ml) or inomycin (1 mg/ml) plus PMA (20 ng/ml), respectively. Supernatants of the cells were harvested 24 h later for IL-2 and 48 h later for IFN-g, IL-10, IL-4 and TGF-b assay using a sandwich ELISA. The ELISA kits used in this study were purchased from Biosource (IL-2), R&D (TGF-b) and BD Pharmingen (IL-10, IL-4 and IFN-g), respectively. Serum TGF-b levels of the prediabetic or GAD-IgG-protected NOD mice were detected as the instructions of the manufacturers.
CD4
+ CD25 + and CD4 + CD25 À T cells purification and coculture assay 
FACS analysis
Spleen, inguinal lymph nodes and thymic cells were stained for surface antigens and analyzed by flow cytometry using standard methods. The following conjugated antibodies were purchased from commercial sources: FITC-conjugated anti-mouse CD4 monoclonal antibody (Caltag), PE-conjugated anti-mouse CD25 monoclonal antibody (Caltag), PE-conjugated antimouse CD62L monoclonal antibody (eBioscience). Data were acquired on a Becton Dickson FACScan and analyzed using the CELLQuest software.
Histopathology
Sections of frozen pancreas were used for conventional histopathology. Sections were stained with hematoxylin and eosin to detect the mononuclear cell infiltration.
Statistical analysis
The Students' t-test was used to evaluate significance for each immunological experiment. Values of Po0.05 were considered significant.
